Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance

T-cell antitumor responses can drive immune evasion and suppression in the pancreatic cancer tumor microenvironment. Targeting JAK/STAT signaling using ruxolitinib can overcome these immunosuppressive mechanisms, as well as improve anti–PD-1 efficacy. Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. Pancreatic tumors are minimally infiltrated by T cells and are largely refractory to immunotherapy. Accordingly, the role of T-cell immunity in pancreatic cancer has been somewhat overlooked. Here, we hypothesized that immune resistance in pancreatic cancer was induced in response to antitumor T-cell immune responses and that understanding how pancreatic tumors respond to immune attack may facilitate the development of more effective therapeutic strategies. We now provide evidence that T-cell–dependent host immune responses induce a PDAC-derived myeloid mimicry phenomenon and stimulate immune resistance. Three KPC mouse models of pancreatic cancer were used: the mT3-2D (Kras+/LSL-G12D; Trp53+/LSL-R172H; Pdx1-Cre) subcutaneous and orthotopic models, as well as the KP1 (p48-CRE/LSL-Kras/Trp53flox/flox) subcutaneous model. KPC cancer cells were grown in immunocompetent and immunodeficient C57BL/6 mice and analyzed to determine the impact of adaptive immunity on malignant epithelial cells, as well as on whole tumors. We found that induced T-cell antitumor immunity, via signal transducer and activator of transcription 1 (STAT1), stimulated malignant epithelial pancreatic cells to induce the expression of genes typically expressed by myeloid cells and altered intratumoral immunosuppressive myeloid cell profiles. Targeting the Janus Kinase (JAK)/STAT signaling pathway using the FDA-approved drug ruxolitinib overcame these tumor-protective responses and improved anti–PD-1 therapeutic efficacy. These findings provide future directions for treatments that specifically disable this mechanism of resistance in PDAC.

[1]  L. Weiner,et al.  T-Cell Immunity in Pancreatic Cancer , 2020, Pancreas.

[2]  A. Biankin,et al.  Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma. , 2020, Cancer discovery.

[3]  K. Murphy,et al.  Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. , 2020, Cancer cell.

[4]  Malachi Griffith,et al.  pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens , 2020, Cancer Immunology Research.

[5]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Nancy R. Zhang,et al.  Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade , 2019, Cell.

[7]  Yun-Gui Yang,et al.  Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma , 2019, Cell Research.

[8]  Michael C. Schmid,et al.  Macrophage-Mediated Subversion of Anti-Tumour Immunity , 2019, Cells.

[9]  M. Sakamoto,et al.  Characterization of spatial distribution of tumor-infiltrating CD8+ T cells refines their prognostic utility for pancreatic cancer survival , 2019, Modern Pathology.

[10]  V. Balachandran,et al.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. , 2019, Gastroenterology.

[11]  L. Weiner,et al.  SpCas9-expression by tumor cells can cause T cell-dependent tumor rejection in immunocompetent mice , 2019, Oncoimmunology.

[12]  E. Fertig,et al.  A Mechanism of Resistance to Antibody-Targeted Immune Attack , 2018, Cancer Immunology Research.

[13]  Zong-fang Li,et al.  CCL9/CCR1 induces myeloid‑derived suppressor cell recruitment to the spleen in a murine H22 orthotopic hepatoma model. , 2018, Oncology reports.

[14]  Minoru Kanehisa,et al.  New approach for understanding genome variations in KEGG , 2018, Nucleic Acids Res..

[15]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[16]  N. Merchant,et al.  Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. , 2018, Cancer research.

[17]  S. Lowe,et al.  Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy , 2018, Immunity.

[18]  A. Biankin,et al.  CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype , 2018, Cell reports.

[19]  P. Scheet,et al.  Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression , 2018, Clinical Cancer Research.

[20]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[21]  Kebin Liu,et al.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer , 2017, Oncoimmunology.

[22]  Michael C. Ostrowski,et al.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer , 2016, Gut.

[23]  A. Maitra,et al.  Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma , 2016, Scientific Reports.

[24]  F. Cunningham,et al.  The Ensembl Variant Effect Predictor , 2016, Genome Biology.

[25]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[26]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[27]  P. Wegman,et al.  Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained by cellular interaction , 2015, BMC Cancer.

[28]  Piet Demeester,et al.  FlowSOM: Using self‐organizing maps for visualization and interpretation of cytometry data , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[29]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[30]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[31]  E. Furth,et al.  Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.

[32]  M. Spector,et al.  Organoid Models of Human and Mouse Ductal Pancreatic Cancer , 2015, Cell.

[33]  J. Sidney,et al.  Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity , 2014, The Journal of experimental medicine.

[34]  M. Taketo,et al.  CCR1-mediated accumulation of myeloid cells in the liver microenvironment promoting mouse colon cancer metastasis , 2014, Clinical & Experimental Metastasis.

[35]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[36]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[37]  Constance Auvynet,et al.  Control of both myeloid cell infiltration and angiogenesis by CCR1 promotes liver cancer metastasis development in mice. , 2013, Neoplasia.

[38]  Y. Kanai,et al.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.

[39]  A. Berg,et al.  Circulating Tumor Cells in Melanoma Patients , 2012, PloS one.

[40]  C. Galbán,et al.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. , 2012, The Journal of clinical investigation.

[41]  M. Aoki,et al.  Inactivation of chemokine (C-C motif) receptor 1 (CCR1) suppresses colon cancer liver metastasis by blocking accumulation of immature myeloid cells in a mouse model , 2010, Proceedings of the National Academy of Sciences.

[42]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[43]  K. Früh,et al.  Human Cytomegalovirus Induces the Interferon Response via the DNA Sensor ZBP1 , 2009, Journal of Virology.

[44]  Xiao-Feng Sun,et al.  Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time , 2009, International journal of cancer.

[45]  G. Daley,et al.  ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. , 2009, Blood.

[46]  J. O’Shea,et al.  Janus kinases in immune cell signaling , 2009, Immunological reviews.

[47]  O. Stål,et al.  Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival , 2008, International journal of cancer.

[48]  A. Chakraborty,et al.  Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis , 2008, Nature Reviews Cancer.

[49]  N. Minato,et al.  SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion , 2007, Nature Genetics.

[50]  D. Gabrilovich,et al.  STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion1 , 2005, The Journal of Immunology.

[51]  E. Scott,et al.  Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion , 2002, Nature.

[52]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[53]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .